Nasus Pharma Ltd. (NSRX) financials
For fiscal 2025 (ended Dec 31, 2025), Nasus Pharma Ltd. reported $1.24B of revenue and -$5.86M of net income.
Some numbers below look mis-scaled in the data Nasus Pharma Ltd. filed with the SEC. Check the filing itself before using them.
- Revenue, FY2025
- $1.24B
- Net income, FY2025
- -$5.86M
- Net margin
- -0.5%
- Free cash flow, FY2025
- -$4.93M
- EPS, diluted, FY2025
- -$0.72
- Cash
- $1.24M
- P/S
- 0.03
- Market cap
- $35.0M
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Revenue | $1.24B | - | - |
| Research and development | $2.24M | $335.0K | $567.0K |
| Selling, general and admin | $2.67M | $743.0K | $580.0K |
| Operating income | -$4.90M | -$1.08M | -$1.15M |
| Interest expense | -$78.0K | $29.0K | $49.0K |
| Net income | -$5.86M | -$1.53M | -$1.05M |
| EPS, basic | -$0.72 | -$0.22 | -$0.15 |
| EPS, diluted | -$0.72 | -$0.22 | -$0.20 |
| Diluted shares | 8.0M | 7.0M | 7.1M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Cash and equivalents | $1.24M | $284.0K | $193.0K |
| Current assets | $4.86M | $457.0K | - |
| Total assets | $5.00M | $717.0K | - |
| Current liabilities | $2.16M | $3.93M | - |
| Total liabilities | $2.24M | $3.93M | - |
| Shareholders' equity | $2.77M | -$3.21M | -$3.80M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Operating cash flow | -$4.92M | -$665.0K | -$1.03M |
| Capital expenditures | $14.0K | - | - |
| Free cash flow | -$4.93M | - | - |
| Investing cash flow | -$3.01M | - | - |
| Financing cash flow | $8.92M | $770.0K | $1.05M |
| Stock-based compensation | $447.0K | $10.0K | $39.0K |
Key ratios
Source: XBRL data Nasus Pharma Ltd. files with the SEC, latest filing dated Mar 25, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
NSRX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| NSRX | $1.24B | - | -$5.86M | -0.5% | $35.0M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.35T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $675.92B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $519.48B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $364.98B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $311.52B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.61B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.31B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $180.22B |
NSRX FAQ
7 questionsWhat is NSRX revenue?
Nasus Pharma Ltd. (NSRX) reported $1.24B of revenue for fiscal 2025 (ended Dec 31, 2025).Is NSRX profitable?
No. Nasus Pharma Ltd. reported a net loss of $5.86M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does NSRX have?
Nasus Pharma Ltd. reported $1.24M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is NSRX free cash flow?
Nasus Pharma Ltd. generated -$4.93M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -$4.92M less capital expenditures.What is NSRX earnings per share?
Diluted earnings per share were -$0.72 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did NSRX last report financial results?
The latest statements here come from Nasus Pharma Ltd.'s 20-F filed on Mar 25, 2026, covering the period ended Dec 31, 2025.Where does this NSRX financial data come from?
Quantisnow builds these statements from the structured XBRL data Nasus Pharma Ltd. files with the SEC. It is provided for information only and is not investment advice.